Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4511 - Evolution in Neutrophil-to-lymphocyte ratio (NLR) among advanced Soft Tissue Sarcoma (STS) patients treated with pazopanib within EORTC 62043/62072 trials


11 Sep 2017


Poster display session


Cytotoxic Therapy;  Soft Tissue Sarcomas


Eleonora De Maio


Annals of Oncology (2017) 28 (suppl_5): v521-v538. 10.1093/annonc/mdx387


E. De Maio1, N. Touati2, S. Litière3, S. Sleijfer4, W.T.A. van der Graaf5, A. Le Cesne6, L. D'Ambrosio7, P.G.G. Casali8, A. Italiano9, I. Desar10, A. Gronchi11

Author affiliations

  • 1 Eortc, European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 2 Statistics, EORTC, 1200 - Brussels/BE
  • 3 Statistics, EORTC - European Organisation for Research and Treatment of Cancer, 1200 - Brussels/BE
  • 4 Medical Oncology, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL
  • 5 Medical Oncology, Royal Marsden Hospital NHS Foundation Trust, SW3 6JJ - London/GB
  • 6 Department Of Medical Oncology, Gustave Roussy Cancer Campus, 94805 - Villejuif/FR
  • 7 Medical Oncology, IRCCS Istituto di Candiolo, 10060 - Candiolo/IT
  • 8 Adult Mesenchymal Tumour And Rare Cancer Medical Oncology Unit, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 9 Medicine, Institute Bergonié, 33076 - Bordeaux/FR
  • 10 Medical Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 11 Department Of Surgery, Fondazione IRCCS - Istituto Nazionale dei Tumori, 20133 - Milan/IT


Abstract 4511


A high NLR has been shown to be associated with a poor prognosis in several solid tumors including STS and might be helpful for patient stratification and individual risk assessment. The aims of this study were to confirm that higher NLR at baseline is associated with worse prognosis in STS and to evaluate if an early decline of NLR during treatment with pazopanib is associated with a more favorable prognosis.


The single-arm phase II EORTC 62043 and placebo-controlled phase III EORTC 62072 were both investigating the effect of pazopanib in patients with advanced STS. We evaluated NLR at baseline and 50 days later. Multivariate analyses on pazopanib-treated patients investigated the prognostic value on both Progression-Free Survival (PFS) and Overall Survival (OS) of NLR at baseline as well as the predictive value of changes in NLR from baseline to the 50-days landmark. Sensitivity analyses were conducted on the placebo-treated patients.


Among the 333 eligible patients treated with pazopanib, a NLR at baseline ≥3 was associated with shorter PFS and OS in comparison to NLR


In this study, limited by its retrospective design, the prognostic value of NLR at baseline was confirmed in advanced STS patients, irrespective of treatment. Changes in NLR during the first 50 days of treatment with pazopanib were not associated with patient outcome and can therefore not be used as an early marker for response.

Clinical trial identification

Legal entity responsible for the study





A. Le Cesne: Pfizer, Lilly, Amgen, Novartis, Pharmamar Honoraria, myself, compensated. P.G. Casali: Consultant/Advisory, Honoraria and Research funds (for the institution) from Amgen, Dompé, Bayer, Blueprint Medicines, Eisai, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Merck SD, Merck Serono, Nektar Therapeutics, Novartis, Pfizer and PharmaMar. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.